Skip to main content

GLP-3 Peptide: Does It Exist & What Are People Actually Searching For?

Short answer: there is no drug, hormone, or receptor called GLP-3. The term is internet shorthand, and almost everyone typing it is looking for a newer multi-receptor agonist, usually retatrutide. This guide explains where the "GLP-3" label came from, what the real incretin peptide family looks like, and which medication you probably want.

Does a GLP-3 Peptide Actually Exist?

No. There is no peptide hormone named glucagon-like peptide-3, no GLP-3 receptor, and no medicine approved or in trials under that name. The naming looks like it should follow GLP-1 and GLP-2, but biology does not work that way. GLP-1 and GLP-2 are two distinct products of the same precursor gene, proglucagon. There is no third numbered member of that series.

So when a product or forum post references a "GLP-3 peptide," it is using a nickname, not a scientific term. The real target of nearly all these searches is a triple receptor agonist, and the most prominent one is retatrutide.

Where the "GLP-3" Term Came From

The label spread through a simple counting habit. Semaglutide activates one receptor pathway (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP, and glucagon). People started numbering the generations: first-gen GLP-1, second-gen "GLP-2" for tirzepatide, third-gen "GLP-3" for retatrutide.

It is memorable, but it collides with real terminology. GLP-2 is already a distinct gut hormone that regulates intestinal growth, unrelated to weight-loss drugs. And tirzepatide is a GLP-1/GIP agonist, not a "GLP-2 drug." The shorthand confuses more than it clarifies, which is exactly why this page exists.

The Real Incretin & Proglucagon Peptide Family

The hormones that matter for metabolic drugs are GLP-1, GIP, and glucagon, plus amylin as a related target. Here is what each one actually does:

  • GLP-1: boosts insulin after meals, slows gastric emptying, and reduces appetite. The target of semaglutide and liraglutide.
  • GIP: a second incretin that adds insulin sensitivity and appetite effects. Tirzepatide adds GIP on top of GLP-1.
  • Glucagon: raises energy expenditure and mobilizes stored fat. Retatrutide adds glucagon activity to drive larger weight loss.
  • GLP-2: promotes intestinal lining growth. Real, but not a weight-loss target and not what "GLP-2 drug" usually means online.
  • Amylin: a separate satiety hormone. Cagrilintide is an amylin analog used with semaglutide.

For a fuller map of the drugs built on these hormones, see our complete list of GLP-1 medications and the GLP-1 complete guide.

Retatrutide: The Drug People Usually Mean

Retatrutide is Eli Lilly's investigational triple agonist, hitting GLP-1, GIP, and glucagon receptors. That third target, glucagon, is what separates it from tirzepatide and drives its unusually large weight-loss numbers. In the Phase 3 TRIUMPH-1 trial reported in 2026, participants lost roughly 28% of body weight on average at 80 weeks, the highest figure published for this class so far.

If "GLP-3" brought you here, retatrutide is almost certainly the drug you were looking for. Dig into the details in our guides on how retatrutide works, its side effects, weight-loss results, and expected cost.

Triple vs Dual vs Single Agonists

The generational framing people compress into "GLP-1, GLP-2, GLP-3" is really about how many receptors a drug engages:

  • Single (GLP-1): semaglutide, liraglutide. Around 15% average weight loss for semaglutide in STEP 1.
  • Dual (GLP-1/GIP): tirzepatide. Up to about 22.5% in SURMOUNT-1. Compare the two in retatrutide vs tirzepatide.
  • Triple (GLP-1/GIP/glucagon): retatrutide. Roughly 28% in TRIUMPH-1.

More receptors has meant more weight loss on average, but also a different side-effect and safety picture, and only the single and dual agonists are FDA-approved today.

GLP-3 vs GLP-1: What the Nickname Misses

GLP-1 is a genuine hormone with decades of research behind it. The informal "GLP-3" is not a hormone at all, so comparing them like two versions of the same thing is misleading. A cleaner way to think about it: GLP-1 drugs pull one metabolic lever, while retatrutide (the "GLP-3" stand-in) pulls three at once.

If your real question is which approved option fits you, start with GLP-1 for weight loss and peptides for weight loss, since retatrutide is not yet on the market. For the trial-by-trial numbers behind the triple-agonist claim, see retatrutide vs tirzepatide and retatrutide TRIUMPH-1 results.

Other Next-Generation GLP Peptides

Retatrutide is not the only drug in the "next-gen GLP" conversation. Others people conflate with a mythical GLP-3 include:

None is a "GLP-3," but together they cover most of what people mean by the newest wave of GLP drugs.

What Does "GLP-3 RT" Mean?

"RT" is gray-market shorthand for retatrutide. You will see it written as GLP-3 RT, GLP3-RT, or just RT on vendor listings, forum posts, and group-buy spreadsheets. It carries no official meaning. Sellers use the abbreviation partly as convenience and partly to avoid keyword filters on payment processors and ad platforms, which is a reason to be more cautious about the listing rather than less.

Related shorthand you will run into in the same places: "reta" for retatrutide, "tirz" for tirzepatide, "sema" for semaglutide, and "cagri" for cagrilintide. None of these are pharmaceutical designations. A pharmacy label never says RT.

The important part: the abbreviation does not change what the product is. Anything sold as GLP-3 RT is unapproved retatrutide from an unregulated source, with no verified identity, purity, sterility, or dose accuracy. See research peptides for how that supply chain actually works.

"GLP-3" Side Effects: What TRIUMPH-1 Reported

Since "GLP-3" means retatrutide in practice, the relevant safety data comes from the Phase 3 TRIUMPH-1 trial in 2,339 adults. Adverse event rates rose with dose. Reported rates for the 4 mg, 9 mg, and 12 mg arms against placebo:

  • Nausea: 28.6% / 38.4% / 42.4% vs 14.8% on placebo
  • Diarrhea: 25.2% / 34.1% / 32.0% vs 13.5%
  • Constipation: 23.8% / 25.9% / 26.1% vs 10.9%
  • Vomiting: 10.6% / 22.8% / 25.3% vs 4.8%
  • Stopped treatment due to adverse events: 4.1% / 6.9% / 11.3% vs 4.9%

Other reported events included upper respiratory and urinary tract infections and mild to moderate dysesthesia, most of which resolved during continued treatment. The glucagon arm of the molecule also draws cardiovascular attention, since glucagon agonism can raise heart rate.

Two caveats. These rates come from a controlled trial with clinical supervision, structured titration, and pharmaceutical-grade drug. None of those conditions apply to a vial bought online. And these are topline figures from a company announcement; full peer-reviewed data had not published as of this writing.

Fuller breakdown: retatrutide side effects and GLP-1 side effects.

Availability & Legal Status

Retatrutide, the drug behind the "GLP-3" searches, is not FDA-approved and is not legally available by prescription as of 2026. Eli Lilly has said additional Phase 3 readouts, including TRIUMPH-2 in type 2 diabetes and TRIUMPH-3 in established cardiovascular disease, are expected during 2026. No FDA submission date and no decision date have been announced, so any specific launch month circulating online is speculation. See retatrutide availability for the current status.

By contrast, semaglutide and tirzepatide are approved and can be prescribed. If you want a legal option now, those are the real choices, not anything sold as "GLP-3."

Should You Buy Anything Sold as "GLP-3"?

No. Products marketed as "GLP-3 peptide" or gray-market "retatrutide for sale" are unregulated research chemicals. There is no guarantee the vial contains what the label claims, at the stated purity or dose, and dosing errors with potent metabolic peptides can be dangerous. The FDA has flagged fraudulent and mislabeled compounded GLP-1 products, and an unapproved triple agonist bought online carries even less oversight.

The safer path is a licensed provider and an approved medication. Learn what separates legitimate sources from research-chem vendors in what are peptides.

Frequently Asked Questions About GLP-3 Peptide

No. There is no hormone, receptor, or approved drug named GLP-3. The incretin and related peptide family includes GLP-1 (glucagon-like peptide-1), GLP-2, GIP, and glucagon. When people search for "GLP-3 peptide" they are almost always looking for a next-generation multi-receptor agonist, most often retatrutide, which acts on three receptors at once. The "GLP-3" label is informal shorthand that stuck online, not a real biochemical class.

Retatrutide. It is Eli Lilly's investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. Because it hits one more target than tirzepatide (a dual GLP-1/GIP agonist), some people call it a "third-generation GLP" or loosely "GLP-3." In Phase 3 TRIUMPH-1 topline data announced May 21, 2026, retatrutide 12 mg produced 28.3% average body weight loss at 80 weeks (70.3 lb), the highest figure yet for this drug class.

Functionally, when someone says "GLP-3" they usually mean retatrutide, but the name is not accurate. Retatrutide is a triple receptor agonist, not a "GLP-3 receptor" agonist, because no GLP-3 receptor exists. The mislabeling comes from a loose counting logic: semaglutide targets one pathway, tirzepatide two, retatrutide three, so people number them GLP-1, GLP-2, GLP-3. That numbering does not match the real receptor biology.

No legitimate product is sold as "GLP-3." Retatrutide, the drug the term usually refers to, is not FDA-approved and is not available by prescription as of 2026. Anything marketed online as "GLP-3 peptide" or "retatrutide for sale" is an unregulated research chemical of unverified identity, purity, and dose. These are not quality-controlled medicines and carry real safety and legal risk.

GLP-1 is a real gut hormone and the target of drugs like semaglutide (Ozempic, Wegovy). The informal "GLP-3" is not a real hormone at all; it is a nickname for triple agonists like retatrutide that add GIP and glucagon activity on top of GLP-1. So the practical difference is the number of receptors engaged: one for GLP-1 drugs, three for the "GLP-3" shorthand.

Retatrutide has produced larger average weight loss than tirzepatide in trials, but it is still investigational and its full long-term safety profile is not established. Tirzepatide is FDA-approved and has years of post-market data. Stronger weight loss does not automatically mean better for a given person, and the added glucagon activity changes the side effect and metabolic picture. Neither should be used without medical supervision.

RT is gray-market shorthand for retatrutide. You will see GLP-3 RT, GLP3-RT, or plain RT on vendor listings and forum posts. It has no official or pharmaceutical meaning, and the abbreviation is partly used to slip past keyword filters on payment processors and ad platforms. Whatever it is called, the product is unapproved retatrutide from an unregulated source with no verified identity, purity, sterility, or dose accuracy.

Since GLP-3 means retatrutide in practice, the data comes from Phase 3 TRIUMPH-1. Nausea was reported by 28.6%, 38.4%, and 42.4% of the 4 mg, 9 mg, and 12 mg groups versus 14.8% on placebo. Vomiting was 10.6%, 22.8%, and 25.3% versus 4.8%. Diarrhea and constipation followed similar dose-dependent patterns. Participants stopping treatment for adverse events ran 4.1%, 6.9%, and 11.3% versus 4.9% on placebo. Those rates come from a supervised trial using pharmaceutical-grade drug, which is not what you get from an online vial.

Yes. The pipeline includes survodutide (GLP-1/glucagon dual agonist), mazdutide (GLP-1/glucagon), cagrilintide (an amylin analog often paired with semaglutide as CagriSema), and orforglipron (an oral small-molecule GLP-1). None of these is a "GLP-3," but they are the real drugs behind most next-generation GLP searches.